Actinogen Announces Phase 2 Trials in Alzheimer's Disease and Depression SYDNEY, June 14, 2022 (GLOBE NEWSWIRE) -- Actinogen Medical Limited recently announced positive results for Part A of its two-part double-blind placebo-controlled XanaMIA dose-ranging trial, which...